Welcome to our dedicated page for Hca Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HCA Healthcare, Inc. (NYSE: HCA) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. HCA Healthcare is a Nashville-based provider of healthcare services with 191 hospitals and approximately 2,500 ambulatory sites of care, and its filings offer detail on how it finances and governs this network, as well as how it reports operating results to shareholders.
For this issuer, Form 10-K annual reports and Form 10-Q quarterly reports are central sources for information on the performance of its general medical and surgical hospitals and related ambulatory facilities. These filings typically include discussions of segment operations, risk factors relevant to healthcare services, and descriptions of the company’s learning health system approach. On Stock Titan, AI-powered summaries can help explain key sections of lengthy 10-K and 10-Q documents in more accessible language.
HCA Healthcare also uses Form 8-K to report material events. Recent 8-Ks have described items such as the public offering of senior notes by HCA Inc., the company’s direct, wholly owned subsidiary, including the terms of the notes, related indentures and covenants, and the planned redemption of existing senior notes. Other 8-K filings have announced quarterly results, cash dividend declarations on HCA common stock, and changes in the Board of Directors.
Debt investors may focus on filings that describe senior notes, indentures and guarantees, including covenants that limit liens, sale and lease-back transactions, or major corporate reorganizations. Equity investors may review proxy materials and compensation disclosures, along with periodic reports, to understand governance structures and board committee responsibilities, such as the Audit and Compliance Committee and the Patient Safety and Quality of Care Committee.
Through Stock Titan, users can view real-time updates from EDGAR, see insider-related forms such as Form 4 when available, and rely on AI-generated highlights to quickly identify notable changes, obligations and events in HCA Healthcare’s SEC reporting history.
HCA Healthcare (HCA) CEO and director Samuel N. Hazen reported multiple open‑market sales of HCA common stock on February 3, 2026, at weighted average prices ranging from about
On February 4, 2026, Hazen reported a transfer of 1,045 shares at
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe reported two transactions in HCA common stock on February 3, 2026. A transaction coded “S” showed the disposition of 1,500 shares at $498.0901 per share. A second transaction coded “G” reported 4,050 shares at $0 per share. After these transactions, he directly owned 25,952.9017 shares of HCA common stock.
HCA Healthcare, Inc. shareholder plans Rule 144 sale of shares
A shareholder has filed a notice of intent to sell 1,500 shares of HCA Healthcare common stock through Merrill Lynch on the NYSE. The filing lists an aggregate market value of $747,135.15 and indicates an approximate sale date of February 3, 2026.
The shares were acquired on April 29, 2021 through the exercise of a stock appreciation right from HCA Healthcare, described as a compensatory payment. The notice states that the person signing does not know of any undisclosed material adverse information about HCA Healthcare’s current or prospective operations.
HCA Healthcare, Inc. common stock: a shareholder has filed a Form 144 to sell 42,877 common shares through Merrill Lynch on the NYSE, with an aggregate market value of
The shares were acquired on
HCA Healthcare, Inc. reported that its SVP & Controller, Christopher F. Wyatt, received a grant of stock appreciation rights on January 29, 2026. The award covers 2,560 stock appreciation rights with an exercise price of $482.53 per share.
These stock appreciation rights vest in four equal annual installments beginning on January 29, 2027, and are exercisable through January 29, 2036. Following this grant, Wyatt beneficially holds 2,560 derivative securities directly.
HCA Healthcare executive Michael R. McAlevey reported a new equity award. On January 29, 2026, he received 8,067 stock appreciation rights linked to HCA common stock, held as a direct beneficial owner.
The stock appreciation rights carry a $482.53 exercise price and vest in four equal annual installments beginning on January 29, 2027, giving this executive a long-term, performance-linked incentive tied to HCA Healthcare’s share price over time.
HCA Healthcare EVP and CFO Mike A. Marks received a new equity award in the form of stock appreciation rights. On January 29, 2026, he was granted 11,945 stock appreciation rights tied to HCA common stock at an exercise price of $482.53 per share. These rights vest in four equal annual installments beginning January 29, 2027 and expire January 29, 2036. Following this grant, he beneficially holds 11,945 derivative securities directly.
HCA Healthcare CEO Samuel N. Hazen reported several equity compensation moves. On January 29, 2026, he received 55,846 stock appreciation rights with an exercise price of
On January 30, 2026, Hazen exercised 84,360 stock appreciation rights, acquiring 84,360 shares of common stock at
HCA Healthcare EVP and COO Jon M. Foster reported a grant of 11,945 stock appreciation rights (SARs) on HCA common stock at an exercise price of
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe received a grant of 8,067 stock appreciation rights on January 29, 2026. Each right has an exercise price of
The stock appreciation rights vest in four equal annual installments beginning on
FAQ
What is the current stock price of Hca Healthcare (HCA)?
What is the market cap of Hca Healthcare (HCA)?
